ATL 313, a selective A2A adenosine receptor agonist, reduces myocardial infarct size in a rat ischemia/reperfusion model

Open Cardiovascular Medicine Journal

Volumn 3, Issue , 2009, Pages 166-172

  Dai, Wangde ^a   Hale, Sharon L ^a   Nayak, Rohith ^a   Kloner, Robert A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

A2A adenosine receptor; ATL 313; Myocardial infarction

Indexed keywords

4 [3 [6 AMINO 9 (5 CYCLOPROPYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL) 9H PURIN 2 YL]PROP 2 YNYL]PIPERIDINE 1 CARBOXYLIC ACID METHYL ESTER; ADENOSINE A2A RECEPTOR AGONIST; ATL 313; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART RATE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; RISK ASSESSMENT;

EID: 77953435897     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192400903010166     Document Type: Article

References (18)

1. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 2006; 27: 2400-5.
2. Hale SL, Bellows SD, Hammerman H, Kloner RA. An adenosine A1 receptor agonist, R(-)-N-(2-phenylisopropyl)-adenosine (PIA), but not adenosine itself, acts as a therapeutic preconditioning-mimetic agent in rabbits. Cardiovasc Res 1993; 27: 2140-5.
3. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527-52.
4. Lasley RD, Jahania MS, Mentzer RM, Jr. Beneficial effects of adenosine A(2a) agonist CGS-21680 in infarcted and stunned porcine myocardium. Am J Physiol Heart Circ Physiol 2001; 280: H1660-6.
5. Glover DK, Riou LM, Ruiz M, et al. Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium. Am J Physiol Heart Circ Physiol 2005; 288: H1851-8.
6. Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. Circulation 1992; 85: 659-65.
7. Lasley RD, Kristo G, Keith BJ, Mentzer RM, Jr. The A2a/A2b receptor antagonist ZM-241385 blocks the cardioprotective effect of adenosine agonist pretreatment in in vivo rat myocardium. Am J Physiol Heart Circ Physiol 2007; 292: H426-31.
8. Rivo J, Zeira E, Galun E, Einav S, Linden J, Matot I. Attenuation of reperfusion lung injury and apoptosis by A2A adenosine receptor activation is associated with modulation of Bcl-2 and Bax expression and activation of extracellular signal-regulated kinases. Shock 2007; 27: 266-73.
9. Gazoni LM, Laubach VE, Mulloy DP, et al. Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion. J Thorac Cardiovasc Surg 2008; 135: 156-65.
10. Jordan JE, Zhao ZQ, Sato H, Taft S, Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 1997; 280: 301-9.
11. Yang Z, Day YJ, Toufektsian MC, et al. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 2005; 111: 2190-7.
12. Smits GJ, McVey M, Cox BF, Perrone MH, Clark KL. Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J Pharmacol Exp Ther 1998; 286: 611-8.
13. Marala RB, Mustafa SJ. Immunological characterization of adenosine A2A receptors in human and porcine cardiovascular tissues. J Pharmacol Exp Ther 1998; 286: 1051-7.
14. Dobson JG, Jr, Fenton RA. Adenosine A2 receptor function in rat ventricular myocytes. Cardiovasc Res 1997; 34: 337-47.
15. Kilpatrick EL, Narayan P, Mentzer RM, Jr, Lasley RD. Cardiac myocyte adenosine A2a receptor activation fails to alter cAMP or contractility: role of receptor localization. Am J Physiol Heart Circ Physiol 2002; 282: H1035-40.
16. Ramagopal MV, Chitwood RW, Jr, Mustafa SJ. Evidence for an A2 adenosine receptor in human coronary arteries. Eur J Pharmacol 1988; 151: 483-6.
17. Kloner RA, Przylenk K, Whittaker P, Hale S. Preconditioning stimuli and inadvertent preconditioning. J Mol Cell Cardiol 1995; 27: 743-7.
18. Sun WC, Moore JN, Hurley DJ, Vandenplas ML, Linden JM, Murray TF. Pharmacologic characterization of novel adenosine A2A receptor agonists in equine neutrophils. Am J Vet Res 2007; 68: 981-7.